TERT and glioblastoma: PTPRZ1 is a clinically relevant antibody in glioblastoma associated with stemness (181), and telomerase (TRT) is a major oncogene, whose promoter is mutated in approximately 80% of glioblastoma patients and is associated with tumor progression (96, 182, 183).